Summary
Boston Scientific Corporation (BSX) filed an 8-K on May 6, 2024, primarily detailing outcomes from its 2024 Annual Meeting of Stockholders held on May 2, 2024. The most significant event for investors is the stockholder approval of an amendment and restatement of the Company's By-Laws. These amendments introduce updated advance notice requirements for stockholders wishing to propose business or nominate directors, now requiring notice not less than 90 days nor more than 120 days prior to the anniversary of the preceding year's annual meeting. They also enhance compliance with universal proxy rules, including provisions to disregard votes for director nominees if the soliciting stockholder fails to meet Rule 14a-19 requirements. In addition to the by-law changes, the filing confirms the election of all nine director nominees for one-year terms and the advisory approval of executive compensation. The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024 was also ratified. These actions reflect governance updates and routine corporate business conducted at the annual meeting, with the amended By-Laws becoming effective as of May 2, 2024.
Key Highlights
- 1Stockholders approved amendments to the By-Laws regarding advance notice and universal proxy rule updates.
- 2The new By-Laws set the advance notice period for stockholder proposals/director nominations between 90 and 120 days prior to the anniversary of the prior year's annual meeting.
- 3The amendments include stricter compliance requirements for universal proxy rules (Rule 14a-19) for director nominations.
- 4All nine director nominees were elected to the Board of Directors for one-year terms.
- 5The advisory vote on the compensation of Named Executive Officers was approved by stockholders.
- 6Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2024.